These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1977478)

  • 21. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients.
    Caligiuri MP; Lohr JB
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):562-7. PubMed ID: 9447497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor.
    Metzer WS; Paige SR; Newton JE
    Mov Disord; 1993; 8(1):43-6. PubMed ID: 8093548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs.
    Bocola V; Fabbrini G; Sollecito A; Paladini C; Martucci N
    J Neurol Neurosurg Psychiatry; 1996 Feb; 60(2):213-6. PubMed ID: 8708659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia.
    Sandyk R
    Int J Neurosci; 1993 Jun; 70(3-4):193-7. PubMed ID: 8063538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.
    Greenbaum L; Smith RC; Lorberboym M; Alkelai A; Zozulinsky P; Lifschytz T; Kohn Y; Djaldetti R; Lerer B
    Psychopharmacology (Berl); 2012 Apr; 220(3):519-28. PubMed ID: 21947317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action.
    Lidsky TI
    Schizophr Bull; 1995; 21(1):67-74. PubMed ID: 7770742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2 receptors in substantia nigra in schizophrenia.
    Owen R; Owen F; Poulter M; Crow TJ
    Brain Res; 1984 May; 299(1):152-4. PubMed ID: 6144367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose destyrosine-gamma-endorphin in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1982; 78(3):285-6. PubMed ID: 6130557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases].
    Truong DD; Sczesni B; Fahn S; Gross J; Donovan K; van Bakel A; Wiley MK
    Nervenarzt; 1988 Feb; 59(2):103-9. PubMed ID: 2896306
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study.
    Dorfman-Etrog P; Hermesh H; Prilipko L; Weizman A; Munitz H
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):475-7. PubMed ID: 10625114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of neuroleptic-induced parkinsonism in psychotic patients receiving adjunctive electroconvulsive therapy.
    Mukherjee S; Debsikdar V
    Convuls Ther; 1994 Mar; 10(1):53-8. PubMed ID: 7914462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronology of the extrapyramidal effects of neuroleptics, and the nigrostriatal dopaminergic system].
    Petit M; Lepine JP; Lesieur P
    Encephale; 1979; 5(4):297-316. PubMed ID: 42527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for neuroleptic-induced movement disorders.
    Sandyk R; Kay SR; Awerbuch GI; Iacono RP
    Int J Neurosci; 1991 Dec; 61(3-4):149-88. PubMed ID: 1688114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia as a risk factor for negative symptoms.
    Taylor SJ
    Br J Psychiatry; 1994 May; 164(5):701-2. PubMed ID: 7921732
    [No Abstract]   [Full Text] [Related]  

  • 36. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electroconvulsive therapy for persistent neuroleptic-induced akathisia and parkinsonism: a case report.
    Hermesh H; Aizenberg D; Friedberg G; Lapidot M; Munitz H
    Biol Psychiatry; 1992 Feb; 31(4):407-11. PubMed ID: 1348431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics.
    Prosser ES; Csernansky JG; Kaplan J; Thiemann S; Becker TJ; Hollister LE
    J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA antigens in drug-induced parkinsonism.
    Metzer WS; Newton JE; Steele RW; Claybrook M; Paige SR; McMillan DE; Hays S
    Mov Disord; 1989; 4(2):121-8. PubMed ID: 2567491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.